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T
inea pedis is one of the most commonly encountered foot
infections. The fact that in most cases it is easily treatable
yet still prevalent in the general population suggests that
it is often undiagnosed or remains untreated by health care
p rofessionals  and  patients.  The  most  common  agent  is
Trichophyton rubrum, which is often mistaken for dry skin in its
presentation. Treatment should include curative as well as
preventative measures where possible.
EPIDEMIOLOGY
Tinea pedis, fungal infection affecting the skin of the foot, is
p robably  the  most  common  infection  encountered  by
podiatrists and chiropodists. Studies on selected populations
have suggested a wide variation in prevalence ranging from 3 to
51% [1] while estimates in the general population have been
a round 16% [2]. Recently the Achilles study [3] highlighted
that previous surveys were likely to be an underestimate of the
t rue prevalence. In a sample of over 13 000 patients who were
mycologically examined, just under 22% had fungal infection
of the skin. This work also confirmed the re p o rts of others –
that  the  disease  generally  affects  males  three  times  more
f requently and shows a rise in prevalence with increasing age –
60% of elderly patients having evidence of infection [4]. Wi t h
an ageing population one can anticipate a rise in the pre v a l e n c e
of this disord e r.
Key Points 
Tinea pedis affects nearly a quarter of the population
The prevalence increases to 60% in elderly patients
Males are three times more frequently affected
AETIOLOGY
The vast majority of fungal species responsible for tinea pedis
belong to a group known as the dermatophytes. These are
responsible for around 90% of all fungal foot infections [5]
with yeast and non-dermatophyte moulds in the minority, only
accounting for around 10% of foot infections. In Northern
Europe, the causative dermatophytes are almost exclusively
Trichophyton species; particularly T. rubrum, T. mentagrophytes
( v a r.  i n t e rd i g i t a l e)  and  to  a  lesser  extent  E p i d e rm o p h y t o n
floccosum [6]. 
Key Point
Nearly all cases of tinea pedis are due to the dermatophyte 
T. ru b ru m
SUSCEPTIBILITY AND SPREAD OF INFECTION
Most cases of dermatophyte foot infections are due to spre a d
f rom  human  to  human  (anthrophillic  species)  although
occasionally  infections  are  acquired  from  animal  sourc e s
(zoophillic species) such as horses, cats and dogs. Maru y a m a
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et al [7] demonstrated that spread occurs most commonly in
places  where  infected  skin  squames  can  be  shed  and
t r a n s f e rred  to  the  feet  of  healthy  individuals.  Fungal
elements may remain viable in shed squames for up to two
years. 
Once attached to the epidermis, dermatophytes generally
invade  with  hyphae  growing  between  adjacent  epiderm a l
cells  and destroy  keratinocytes  by  the  secretion of  kerati-
n a s e s .
Although, potentially, any individual may be exposed to
viable fungus in this manner not all will develop tinea pedis.
Many practitioners may be aware of this fact having been
exposed to fungal elements daily and not having acquired any
infection. Precipitating factors for fungal foot disease are
outlined in Table 1.
PATHOLOGY AND CHRONIC INFECTION
In  normal  subjects  infection  with  dermatophytes  causes  a
delayed  T-cell  mediated  response  that  causes  an  acute
i n f l a m m a t o ry  eruption.  Growth  factors  are  released  fro m
monocytes  and  lymphocytes  that  increase  epidermal  cell
t u rnover  and  shed  the  invading  fungus  [11].  However,
patients  with  chronic  infections  have  been  shown  to
demonstrate a defective cellular immunity that renders them
incapable of clearing the dermatophyte infection. Linked to
the high prevalence rate  of  fungal dermatoses, it  has been
suggested that about 10–20% of the population may possess
this trait [12].
Key Point 
A section of the general population may have increased
susceptibility to superficial skin infections
CLINICAL RECOGNITION
Tinea pedis presents in a number of forms:
1. Interdigital infection
2. Tinea Incognito
3. Vesicular eruption 
4. Plantar moccasin spread. 
Classic interdigital infection typically arises in the lateral
web spaces. The presence of a dry fissure with pruritis is the
typical sign of resident fungi. The macerated web space may
indicate the presence of Gram-negative bacteria alongside
fungi. Swabbing of moist web spaces is generally less likely to
recover fungal elements as they are often inhibited by the
release of bacterial agents [13]. Clinically, to eradicate a moist
interdigital infection an agent must be selected that has both
antibacterial and antifungal properties.
Key Point 
Moist interdigital spaces often indicate a mixed fungal and 
bacterial skin infection
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Adhesion of fungal  P roper drying of the foot with a towel has 
e l e m e n t s been demonstrated to remove infected
p a rticles [8]
Host skin condition Fungi thrive in a humid, carbon dioxide
rich environment. Skin pH can also make a
d i ff e rence as to whether overt infection
occurs or not. Sebaceous secre t i o n s
contain fatty acids and these can be
fungicidal 
Host immune  Immune response can vary from individual 
re s p o n s e to individual. People with diabetes are at a
slightly higher risk of fungal infections due
to the increased amounts of sugar in
various tissues
G e n e t i c s Studies have shown that particular families
have a genetic predisposition to infection
with T. ru b ru m. This is thought to be an
autosomal dominant trait affecting cell
mediated immunity [9]
S m o k i n g Two studies have re p o rted a higher
incidence of tinea in smokers [3, 10]
Systemic disease Patients with endocrine disorders, vascular
disease and obesity have all demonstrated a
higher risk of developing tinea pedis [3, 10]
Table 1. Risk factors for susceptibility to tinea pedis
Interdigital tinea pedis
Tinea IncognitoTinea pedis
Tinea Incognito is a term coined by dermatologists to
describe the clinical appearance of a fungal infection that has
been treated, inappropriately, by the application of topical
s t e roids.  The  effect  is  that  the  infection  spreads  widely,
typically from the interdigital spaces onto the dorsum and may
appear less florid in its eruption as the immune response is
suppressed.
Vesicular eruption is a less common type characterised by
the formation of vesicles on a background of erythema and
intense itching. These typically arise from the interdigital
spaces but also occur as asymmetrical lesions on the plantar
surface. Zoophilic (animal acquired) species are more likely to
be the causative agents in this variety. Secondary bacterial
infection  may  often  complicate  the  clinical  picture  [14].
Recurrent bouts of inflammation are common with this type.
Plantar moccasin spread, due to T. rubrum is probably the
most common form of tinea pedis. Clinically, it appears as a
dry, powdery eruption on the soles (more evident in skin
creases) with a mildly erythemic background. Owing to the
thickness of the plantar epidermis, itching is often absent in
this form of the disease. Despite its innocuous appearance it is
often the most difficult to detect and eradicate. For many
sufferers the condition is entirely unnoticed as there are no
outward symptoms and the condition is often diagnosed as dry
skin.
Key point 
Many cases of dry skin are in fact tinea pedis due to T. rubrum
Whether many cases of tinea pedis go unnoticed or are
t reated  depends  on  their  presentation.  Maruyama  and
colleagues [15] demonstrated in a population of adults that
treatment was more likely to be sought if itching and erythema
were present. This may help to explain the high prevalence of
T. rubrum infections owing to the lack of symptoms in many
patients. Furthermore, many sufferers were unable to recognise
the disease. 
Key point
Patients are more likely to seek treatment if itching is present
Literature in the last few years has focused on the extent to
which T. rubrum has become almost the ultimate parasite in
this form. Zaias and Rebell [9] described this condition as a
s y n d rome  as  many  patients  with  this  presentation  have
evidence of hand, groin and nail involvement with the plantar
surface infection acting as the source. Chronic infection may
represent a genetic trait in individuals who possess a defective
immune response to this particular agent [16].
Key Point
Patients with tinea pedis may have evidence of infection
elsewhere
WHY TREAT PATIENTS WITH TINEA PEDIS?
For many patients, tinea pedis is nothing more than an
inconvenience and it could be argued that if so many of the
population have it why bother? Fungal skin infection leads to
itching,  erythema  and  fissuring.  However,  for  a  small
percentage of patients a breach in skin integrity may leave
them  vulnerable  to  secondary  bacterial  infection  fro m
staphylcocci and streptococci. The extent of the problem is not
known  but  recent  re s e a rch  has  demonstrated  that  many
patients presenting with cellulitis also have demonstrable,
c o n c u rrent  fungal  foot  infection  [17].  Furt h e rm o re,  the
presence of web space maceration is a known risk factor for the
development of cellulitis. The more web spaces affected – the
higher the risk [18].
DIAGNOSIS
Diagnosis of tinea pedis is often made on clinical grounds
alone but for formal confirmation and identification of the
pathogen a microbiological diagnosis is required. For accurate
diagnosis, it is important to collect a skin sample from an area
likely to contain viable fungus. Clinically, this represents the
edge of a skin lesion – at the interface with healthy skin. In
order to increase the likelihood of a result, sufficient material
should be taken to allow the microbiology laboratory to
undertake microscopy and culture. Specimens may be sent to
the laboratory in coloured cardboard. This allows for easier
collection and processing at the lab. Unlike bacterial swabs,
fungal scrapings can remain viable for many months and so do
not need immediate transport to the laboratory.
Microscopy, although it can be carried out in a clinical
setting, is a skill that can be technically difficult [19]. A sample
skin is placed on a slide and finely sliced with a scalpel. A
solution of 10% potassium hydroxide is added to soften the
sample. After the slide has been warmed gently and left to
clear, a microscopic examination can be carried out. The
presence of fungal hyphae under microscopy is sufficient to
confirm the presence of a fungal infection and treatment can be
commenced.
Culture of specimens is normally carried out by a micro-
biology laboratory. Culture is a means to identify the species as
this may inform choice of treatment. Typically the specimen is
cultured on a medium for 2–3 weeks at 27
OC and examined
regularly for the presence of fungal growth. 
TREATMENT OF TINEA PEDIS
Effective management of tinea pedis should focus on two
aspects: treating the infection and preventing reoccurrence.
For skin infection a number of topical agents are available in
the UK over the counter (Table 2).
Antifungal agents can be described as being either fungi-
cidal or fungistatic in activity, that is, being able to directly kill
fungus or prevent fungal replication and growth, respectively.
Fungicidal agents by their nature tend to be faster to cure.
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Tinea pedis affecting the heelTinea pedis
A systematic review comparing the efficacy of various
agents was undertaken by Hart et al [20]. From this work it
was concluded that azoles, allylamines and undecenoates were
all effective when compared with placebo in controlled trials.
Data  were  also  examined  comparing  azoles  with
allylamines. The findings confirm other research [21] that
allylamines such as terbinafine are more effective than azoles in
the treatment of tinea pedis, in both time to cure and spectrum
of activity. Terbinafine is able to work in around half the time
reflecting the fact that azoles are primarily fungistatic in their
action at this concentration [22] while terbinafine is fungicidal.
Duration of therapy is an important factor in determining
patients’ compliance. On this basis, the more rapid effects of
terbinafine cream may reduce the likelihood of treatment
failures due to non-compliance.
Key point
Allylamines, such as terbinafine, have been found to cure
faster than than azoles (such as clotrimazole and miconazole)
One longer-term study followed up a group of patients
who had received either clotrimazole or terbinafine cream for
interdigital tinea pedis. Based on the available data it was
reported that those using clotrimazole required re-treatment
within 6 months while those on terbinafine remained without
the need for further treatment for around 12 months [23].
Amorolfine cream has been tested independently and has been
shown to be equally effective as terbinafine cream [24]. 
In cases of severe tinea pedis or where a rapid cure is
re q u i red, short courses of oral agents may be indicated such
as oral terbinafine, griseofulvin and itraconazole. The use of
oral terbinafine (250mg/day) for one week has been found to
be  as  effective  as  a  four-week  course  of  clotrimazole  1%
c ream [25].
WHICH DRUGS ARE AVAILABLE FOR SUPPLY TO
PATIENTS?
For skin infection, virtually all topical creams and sprays are
available for supply by podiatrists or from pharmacies and
other retailers. The only exception to this is amorolfine cream
( L o c e ryl®  cream,  Galderma  UK)  which  is  currently  a
prescription only medicine. 
COMBINED TOPICAL ANTIFUNGAL AND TOPICAL
STEROID PREPARATIONS
A  number  of  combination  topical  antifungal  and  stero i d
p reparations are currently available on prescription, indicated
for use in tinea pedis. Evidence for their success in clearing
fungal foot infections compared with plain antifungal agents is
lacking. One American review paper [26] has quoted workers
who suggested that combination therapy of this type is more
expensive, risks higher cutaneous reactions and is generally less
e ffective. This type of preparation is more likely to be pre s c r i b e d
in primary practice, perhaps when the diagnosis is not so clear. 
PREVENTION OF RELAPSE 
Despite  the  availability  of  effective  antifungal  agents,  many
patients suffer with re c u rrent bouts of tinea pedis. Relapse may
result from re o c c u rrence (a previous infection has failed to be fully
eradicated) or from re-infection (an infection is completely cure d
and after a period of time a new infection develops).
Research investigating successful methods to prevent
re o c c u rrence and re-infection are sparse and there f o re suggestions
can only be made. When an infection has apparently cleare d ,
p rophylactic use of topical antifungal agents on a weekly basis
may help to reduce re o c c u rrence. Topical terbinafine has been
shown in studies to remain in the tissues at an active concentration
for  over  7  days  following  cessation  of  treatment  [27,  28].
F u rt h e rm o re,  fungal  spores  (or  art h roconidia)  may  remain  in
footwear and hosiery from which relapse may develop. For this
reason, it is advisable for patients to discard old hosiery and to dis-
infect footwear with a preparation such as terbinafine (Lamisil
AT®) spray, which has been effective in inactivating art h ro c o n i d i a
f rom various species of dermatophytes [29]. Another considera-
tion is that a percentage of patients who have tinea pedis may also
have evidence of fungal infection in other parts of the body, typi-
cally the hands and groin. So, these areas also need to be tre a t e d
e ffectively to prevent re-infection from other parts of the body.
Re-infection can occur in particular individuals who may be
exposed  to  high  levels  of  fungal  elements  (i.e.  sports  club
members, swimmers, etc) or patients at a higher risk of infection
due to underlying diseases such as peripheral vascular disease
and  diabetes,  so  preventative  action  should  be  taken.  Basic
hygiene measures have been shown to be effective. For example,
d rying of feet following deliberate inoculation by derm a t o p h y t e
elements has been shown to be effective in removing them before
an infection is established [8]. Table 3 summarises basic measure s
that may reduce the likelihood of re l a p s e .
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Avoid going barefoot in public places
D ry feet properly after bathing
Encourage prophylactic application of antifungal agents
Check there are no other active sources of infection elsewhere, 
i.e. hands, gro i n
D i s c a rd old footwear and hosiery
E n s u re footwear is properly fitted and not occlusive
H o s i e ry should be natural fibre (i.e. cotton, not nylon or rayon)
and changed re g u l a r l y
E n s u re other family members are free of tinea pedis
Table 3. Recommendations to prevent tinea pedis 
– adapted from [30]
A m o rolfine  Morpholine  L o c e ryl® Cream  POM 
( G a l d e rm a )
C l o t r i m a z o l e A z o l e Canesten AF® cream  O T C
and spray 
(Bayer consumer care )
M i c o n a z o l e A z o l e Daktarin® cream  O T C
( J a n s s e n - C i l a g )
S u l c o n a z o l e A z o l e E x e l d e rm® Cream  O T C
( C e n t r a p h a rm )
Te r b i n a f i n e A l l y l a m i n e Lamisil AT® spray  O T C
and cream (Novart i s )
U n d e c o n o a t e Zinc  Mycota®  O T C
U n d e c o n o a t e ( T h o rnton & Ross)
Table 2. Common agents used in the treatment of tinea pedis
A g e n t Class of Dru g E x a m p l e s Av a i l a b i l i t yTinea pedis
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1 . What is the most common age group affected by tinea pedis?
2 . How common is tinea pedis among the general population?
3 . What is the most common form of presentation of the disease?
4 . W h e re else may fungal infection co-exist?
5 . What factors make some people more susceptible to infection than others?
6 . Outline the main complications associated with fungal skin infection.
7 . How would you confirm a diagnosis of tinea pedis?
8 . What are the main groups of drugs available for treating tinea pedis?
9 . Which agents are considered to be superior in treating the disease? 
1 0 .What advice should be given to patients with fungal foot infection?
P o s t - reading activity
S h o rt Answer QuestionsTinea pedis
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• How often do I often recognise the condition?
• Am I treating the disease effectively and giving the patient the best care possible?
• How do I assess my treatment outcomes?
• How does this article change my practice, if at all? 
R e f l e c t i o n
After reading this CPD article, take a few minutes to reflect on tinea pedis and how it is managed. Areas for reflection may include:
N o t e sTinea pedis
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